Sangamo Therapeutics
SGMO
SGMO
143 hedge funds and large institutions have $467M invested in Sangamo Therapeutics in 2017 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 42 increasing their positions, 34 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
24% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 34
21% more funds holding
Funds holding: 118 → 143 (+25)
14.47% more ownership
Funds ownership: 59.26% → 73.73% (+14%)
Holders
143
Holding in Top 10
3
Calls
$13.2M
Puts
$9.25M
Top Buyers
| 1 | +$22.6M | |
| 2 | +$11.5M | |
| 3 | +$11M | |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.8M |
| 5 |
D.E. Shaw & Co
New York
|
+$8.02M |
Top Sellers
| 1 | -$23M | |
| 2 | -$3.67M | |
| 3 | -$2.87M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.18M |
| 5 |
CCI
Columbus Circle Investors
|
-$1.85M |